114 related articles for article (PubMed ID: 11770703)
1. Treatment-induced expression of anti-apoptotic proteins in WSU-CLL, a human chronic lymphocytic leukemia cell line.
Wall NR; Beck FW; Al-Katib AM; Mohammad RM
J Drug Target; 2001; 9(5):329-39. PubMed ID: 11770703
[TBL] [Abstract][Full Text] [Related]
2. Potentiation of 2-chlorodeoxyadenosine activity by bryostatin 1 in the resistant chronic lymphocytic leukemia cell line (WSU-CLL): association with increased ratios of dCK/5'-NT and Bax/Bcl-2.
Mohammad RM; Beck FW; Katato K; Hamdy N; Wall N; Al-Katib A
Biol Chem; 1998 Oct; 379(10):1253-61. PubMed ID: 9820586
[TBL] [Abstract][Full Text] [Related]
3. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
Mohammad RM; Katato K; Almatchy VP; Wall N; Liu KZ; Schultz CP; Mantsch HH; Varterasian M; al-Katib AM
Clin Cancer Res; 1998 Feb; 4(2):445-53. PubMed ID: 9516935
[TBL] [Abstract][Full Text] [Related]
4. Factors affecting bryostatin 1-enhanced 2-CdA cytotoxicity in resistant B-cell chronic lymphocytic leukemia.
Beck FW; Eilender DS; Dandashi MH; Siddiq F; Snell DC; Godmere MA; Al-Katib AM; Mohammad RM
Int J Mol Med; 2004 Jul; 14(1):113-9. PubMed ID: 15202025
[TBL] [Abstract][Full Text] [Related]
5. Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report.
Ahmad I; Al-Katib AM; Beck FW; Mohammad RM
Clin Cancer Res; 2000 Apr; 6(4):1328-32. PubMed ID: 10778958
[TBL] [Abstract][Full Text] [Related]
6. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.
Mohammad RM; Limvarapuss C; Hamdy N; Dutcher BS; Beck FW; Wall NR; Al-Katib AM
Int J Oncol; 1999 May; 14(5):945-50. PubMed ID: 10200346
[TBL] [Abstract][Full Text] [Related]
7. Similarities between the sensitivity to 2-chlorodeoxyadenosine of lymphocytes from CLL patients and bryostatin 1-treated WSU-CLL cells: an infrared spectroscopic study.
Liu KZ; Schultz CP; Mohammad RM; Al-Katib AM; Johnston JB; Mantsch HH
Cancer Lett; 1998 May; 127(1-2):185-93. PubMed ID: 9619876
[TBL] [Abstract][Full Text] [Related]
8. Bryostatin 1-induced modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells.
Beck FW; Al-Katib AM; Ahmad I; Wall NR; Liu KZ; Mantsch HH; Mohammad RM
Int J Mol Med; 2000 Apr; 5(4):341-7. PubMed ID: 10719048
[TBL] [Abstract][Full Text] [Related]
9. Infrared spectroscopic study of bryostatin 1-induced membrane alterations in a B-CLL cell line.
Liu KZ; Schultz CP; Johnston JB; Beck FW; Al-Katib AM; Mohammad RM; Mantsch HH
Leukemia; 1999 Aug; 13(8):1273-80. PubMed ID: 10450757
[TBL] [Abstract][Full Text] [Related]
10. Bryostatin induces protein kinase C modulation, Mcl-1 up-regulation and phosphorylation of Bcl-2 resulting in cellular differentiation and resistance to drug-induced apoptosis in B-cell chronic lymphocytic leukemia cells.
Thomas A; Pepper C; Hoy T; Bentley P
Leuk Lymphoma; 2004 May; 45(5):997-1008. PubMed ID: 15291360
[TBL] [Abstract][Full Text] [Related]
11. The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
Mohammad RM; Wall NR; Dutcher JA; Al-Katib AM
Clin Cancer Res; 2000 Dec; 6(12):4950-6. PubMed ID: 11156256
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced apoptosis in chronic lymphocytic leukemia.
Stoetzer OJ; Pogrebniak A; Scholz M; Pelka-Fleischer R; Gullis E; Darsow M; Nüssler V; Wilmanns W
Leukemia; 1999 Nov; 13(11):1873-80. PubMed ID: 10557065
[TBL] [Abstract][Full Text] [Related]
13. Bryostatin and CD40-ligand enhance apoptosis resistance and induce expression of cell survival genes in B-cell chronic lymphocytic leukaemia.
Kitada S; Zapata JM; Andreeff M; Reed JC
Br J Haematol; 1999 Sep; 106(4):995-1004. PubMed ID: 10520003
[TBL] [Abstract][Full Text] [Related]
14. Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage.
Nabha SM; Mohammad RM; Dandashi MH; Coupaye-Gerard B; Aboukameel A; Pettit GR; Al-Katib AM
Clin Cancer Res; 2002 Aug; 8(8):2735-41. PubMed ID: 12171907
[TBL] [Abstract][Full Text] [Related]
15. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-beta-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2.
Wang S; Vrana JA; Bartimole TM; Freemerman AJ; Jarvis WD; Kramer LB; Krystal G; Dent P; Grant S
Mol Pharmacol; 1997 Dec; 52(6):1000-9. PubMed ID: 9396780
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment of human chronic lymphocytic leukemia xenografts with combination biological agents auristatin PE and bryostatin 1.
Mohammad RM; Varterasian ML; Almatchy VP; Hannoudi GN; Pettit GR; Al-Katib A
Clin Cancer Res; 1998 May; 4(5):1337-43. PubMed ID: 9607595
[TBL] [Abstract][Full Text] [Related]
17. Bryostatin 1 enhances paclitaxel-induced mitochondrial dysfunction and apoptosis in human leukemia cells (U937) ectopically expressing Bcl-xL.
Wang S; Wang Z; Boise LH; Dent P; Grant S
Leukemia; 1999 Oct; 13(10):1564-73. PubMed ID: 10516758
[TBL] [Abstract][Full Text] [Related]
18. 2-chlorodeoxyadenosine (2-CdA) does not change the expression of Fas antigen on chronic lymphocytic leukaemia cells.
Gora-Tybor J; Lech-Miranda E; Blonski JZ; Robak T
Adv Exp Med Biol; 2000; 486():307-10. PubMed ID: 11783506
[No Abstract] [Full Text] [Related]
19. P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia.
Johnston JB; Daeninck P; Verburg L; Lee K; Williams G; Israels LG; Mowat MR; Begleiter A
Leuk Lymphoma; 1997 Aug; 26(5-6):435-49. PubMed ID: 9389352
[TBL] [Abstract][Full Text] [Related]
20. 2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells.
Steele AJ; Prentice AG; Hoffbrand AV; Yogashangary BC; Hart SM; Lowdell MW; Samuel ER; North JM; Nacheva EP; Chanalaris A; Kottaridis P; Cwynarski K; Wickremasinghe RG
Blood; 2009 Aug; 114(6):1217-25. PubMed ID: 19515722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
